BR112021018973A2 - Formulação de combinação tripla de baixa dose - Google Patents
Formulação de combinação tripla de baixa doseInfo
- Publication number
- BR112021018973A2 BR112021018973A2 BR112021018973A BR112021018973A BR112021018973A2 BR 112021018973 A2 BR112021018973 A2 BR 112021018973A2 BR 112021018973 A BR112021018973 A BR 112021018973A BR 112021018973 A BR112021018973 A BR 112021018973A BR 112021018973 A2 BR112021018973 A2 BR 112021018973A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination formulation
- triple combination
- low dose
- dose
- biguanide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823575P | 2019-03-25 | 2019-03-25 | |
| PCT/IB2020/000141 WO2020194046A1 (en) | 2019-03-25 | 2020-03-25 | Low-dose triple combination formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018973A2 true BR112021018973A2 (pt) | 2022-02-01 |
Family
ID=72611638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018973A BR112021018973A2 (pt) | 2019-03-25 | 2020-03-25 | Formulação de combinação tripla de baixa dose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220184070A1 (https=) |
| EP (1) | EP3946343A4 (https=) |
| JP (1) | JP2022529312A (https=) |
| KR (1) | KR20220004026A (https=) |
| CN (1) | CN113905738A (https=) |
| AU (1) | AU2020245801A1 (https=) |
| BR (1) | BR112021018973A2 (https=) |
| CA (1) | CA3134799A1 (https=) |
| MX (1) | MX2021011745A (https=) |
| TW (1) | TW202102208A (https=) |
| WO (1) | WO2020194046A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102019112190A1 (de) | 2019-05-09 | 2020-11-12 | Mack Rides Gmbh & Co. Kg | Sperrvorrichtung eines Sicherheitsbügels, Fahrgastaufnahme sowie Vergnügungsfahrgeschäft mit einer solchen Sperrvorrichtung |
| MX2022015333A (es) * | 2020-09-02 | 2023-01-11 | Laboratorios Silanes S A De C V | Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2. |
| CN113559088A (zh) * | 2021-01-21 | 2021-10-29 | 江苏宇锐医药科技有限公司 | 一种含二甲双胍和西格列汀的复方降糖药物制剂 |
| PE20251270A1 (es) * | 2022-08-24 | 2025-05-14 | Dong A St Co Ltd | Formulacion oral compuesta que comprende evogliptina y metformina, y metodos de preparacion de la misma |
| WO2025090920A1 (en) * | 2023-10-25 | 2025-05-01 | Piton Therapeutics, Inc. | Compositions and methods for treating dysfunction of glucose metabolism and/or regulation |
| CN117599008A (zh) * | 2023-11-14 | 2024-02-27 | 华中药业股份有限公司 | 一种西格列汀二甲双胍缓释片及其制作方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0616694B8 (pt) * | 2005-09-29 | 2021-05-25 | Novartis Ag | processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis |
| JP5685550B2 (ja) * | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| US20160151382A1 (en) * | 2013-10-08 | 2016-06-02 | Kevin Ray Pickering | Cooperative Medication Combination Systems |
| WO2016040462A2 (en) * | 2014-09-09 | 2016-03-17 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| KR20180002460A (ko) * | 2016-06-29 | 2018-01-08 | 주식회사 엘지화학 | 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법 |
-
2020
- 2020-03-25 TW TW109110097A patent/TW202102208A/zh unknown
- 2020-03-25 US US17/598,122 patent/US20220184070A1/en not_active Abandoned
- 2020-03-25 MX MX2021011745A patent/MX2021011745A/es unknown
- 2020-03-25 CA CA3134799A patent/CA3134799A1/en active Pending
- 2020-03-25 BR BR112021018973A patent/BR112021018973A2/pt not_active IP Right Cessation
- 2020-03-25 JP JP2021556883A patent/JP2022529312A/ja active Pending
- 2020-03-25 WO PCT/IB2020/000141 patent/WO2020194046A1/en not_active Ceased
- 2020-03-25 EP EP20777507.3A patent/EP3946343A4/en not_active Withdrawn
- 2020-03-25 AU AU2020245801A patent/AU2020245801A1/en not_active Abandoned
- 2020-03-25 KR KR1020217033516A patent/KR20220004026A/ko not_active Ceased
- 2020-03-25 CN CN202080039014.8A patent/CN113905738A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020245801A1 (en) | 2021-11-11 |
| CA3134799A1 (en) | 2020-10-01 |
| JP2022529312A (ja) | 2022-06-21 |
| KR20220004026A (ko) | 2022-01-11 |
| US20220184070A1 (en) | 2022-06-16 |
| EP3946343A1 (en) | 2022-02-09 |
| TW202102208A (zh) | 2021-01-16 |
| CN113905738A (zh) | 2022-01-07 |
| WO2020194046A1 (en) | 2020-10-01 |
| EP3946343A4 (en) | 2022-12-28 |
| MX2021011745A (es) | 2021-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021018973A2 (pt) | Formulação de combinação tripla de baixa dose | |
| BR112021018994A2 (pt) | Formulação de combinação tripla de baixa dose | |
| PE20212249A1 (es) | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| ECSP078023A (es) | Ingrediente farmacéutico activo en base a canabinoide | |
| AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| MX2024004131A (es) | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| MX2021012487A (es) | Compuestos derivados de pirazolopirazina, composicion farmaceutica y uso de la misma. | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| MX2017011499A (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| CL2024003507A1 (es) | Compuestos aromáticos que contienen boro y análogos de insulina relacionados | |
| AR062779A1 (es) | Tratamiento de la esclerosis multiple (em) | |
| BR112012026005A2 (pt) | composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados | |
| BR112023015913A2 (pt) | Compostos novos | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| PE20231943A1 (es) | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma | |
| MX2024010392A (es) | Remibrutinib para el uso en el tratamiento de hidradenitis supurativa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |